NCT06022614View on ClinicalTrials.gov

Effect of Adding Dexmedetomidine As Adjuvant to Bupivacaine in US Guided ESPB for Post MRM Pain Management

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 15, 2023

Primary Completion Date

June 1, 2024

Study Completion Date

July 1, 2024

Conditions
Erector Spinae Plane Block
Interventions
DRUG

Use Bupivacaine 0.25% Injectable Solution

Group A Patients receiving 20 ml Bupivacaine 0.25% added to 1 ml normal saline.

DRUG

Bupivacaine 0.25% Injectable Solution plus Dexmedetomidine

Group B Patients receiving 20 ml Bupivacaine 0.25% added to 1 ml dexmedetomidine

Trial Locations (1)

1181

Faculty of Medicine Ain Shams University, Cairo

All Listed Sponsors
lead

Abanoub Habib

OTHER